NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Amphastar Pharmaceuticals Inc is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.
Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and commercializes generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredients. It markets prescription drugs and one over-the-counter product, including BAQSIMI glucagon nasal powder and Primatene MIST. The company operates in the injectable and inhalation drug markets.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Amphastar Pharmaceuticals Inc stock.
Undervalued: intrinsic value $49.78 per share, market price $27.72, margin of safety 44.3% (as of 2026-10-30).
Discounting its cash flows at 8.3% (average of 3 methods) values the shares at $49.78; the price of $27.72 is 44% below that value, and 79% of that value comes from beyond year five.
Leak Score: 72/100 on 12 of 12 signals (Clear Leak).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
AMPH is undervalued (as of the 2026-10-30 close). Discounting its cash flows at 8.3% (average of 3 methods) values the shares at $49.78; the price of $27.72 is 44% below that value, and 79% of that value comes from beyond year five.
$49.78 per share (as of the 2026-10-30 close), against a market price of $27.72. That is a margin of safety of 44.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
72 out of 100, which we rate "Clear Leak", on 12 of 12 value investing signals.